Jeffrey Hyams

BACKGROUND: Tumor necrosis factor inhibitors (TNFi) are a mainstay of pediatric Crohn’s disease (PCD) therapy; yet not all patients respond, and others lose response over time. Combination therapy with methotrexate may improve response; however, this has not been rigorously evaluated…

BACKGROUND: Tumor necrosis factor inhibitors (TNFi) are a mainstay of pediatric Crohn’s disease (PCD) therapy; yet not all patients respond, and others lose response over time. Combination therapy with methotrexate may improve response; however, this has not been rigorously evaluated…

BACKGROUND: The low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet, which restricts FODMAP intake, currently is used as a treatment for pain-related disorders of gut-brain interaction (DGBI)…

INTRODUCTION: Chronic nausea and abdominal pain are debilitating symptoms that often co-exist in children with functional abdominal pain disorders (FAPD). Standard medical therapy (SMT) includes the off-label medications, cyproheptadine and amitriptyline…

BACKGROUND: Given the variable response to anti-TNF therapy in patients with Crohn’s disease (CD), we hypothesized there is a core biologic (inflammatory) signature associated with early response and endoscopic healing (EH)…

BACKGROUND: Prior pharmacokinetic (PK) investigations have identified an association between anti-TNF trough concentrations (cTrough) and clinical or biochemical remission for children with Crohn’s Disease (CD)…